Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Q2FY22"

33 News Found

Aster DM Healthcare PAT at Rs 107 cr. in Q2FY22
News | November 13, 2021

Aster DM Healthcare PAT at Rs 107 cr. in Q2FY22

Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021


Natco Pharma PAT at Rs 65.1 cr. in Q2FY22
News | November 12, 2021

Natco Pharma PAT at Rs 65.1 cr. in Q2FY22

Natco Pharma has reported consolidated financial results for the period ended September 30, 2021


Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22
News | November 12, 2021

Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22

Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.


J.B Chemicals & Pharmaceuticals PAT at Rs 98 cr. in Q2FY22
News | November 12, 2021

J.B Chemicals & Pharmaceuticals PAT at Rs 98 cr. in Q2FY22

J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021


Alembic Pharma PAT at Rs 169.29 cr. in Q2FY22
News | November 11, 2021

Alembic Pharma PAT at Rs 169.29 cr. in Q2FY22

The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.


Metropolis Healthcare PAT at Rs 58.26 cr in Q2FY22
News | November 11, 2021

Metropolis Healthcare PAT at Rs 58.26 cr in Q2FY22

Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021


AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22
News | November 10, 2021

AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22

The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Marksons Pharma PAT slips to Rs 46.28 in Q2FY22
News | November 10, 2021

Marksons Pharma PAT slips to Rs 46.28 in Q2FY22

Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021


Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
News | November 10, 2021

Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22

Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021


Wockhardt PAT at Rs 33.53 cr. in Q2FY22
News | November 09, 2021

Wockhardt PAT at Rs 33.53 cr. in Q2FY22

The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.